CapWealth Advisors LLC Lowers Position in Gilead Sciences, Inc. $GILD

CapWealth Advisors LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,607 shares of the biopharmaceutical company’s stock after selling 9,320 shares during the period. Gilead Sciences comprises about 1.8% of CapWealth Advisors LLC’s portfolio, making the stock its 21st largest position. CapWealth Advisors LLC’s holdings in Gilead Sciences were worth $27,040,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of GILD. GoalVest Advisory LLC boosted its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC acquired a new position in Gilead Sciences during the 3rd quarter worth about $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth about $27,000. Putney Financial Group LLC grew its position in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute purchased a new stake in Gilead Sciences during the second quarter worth about $30,000. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $100.00 to $103.00 and gave the company a “sector perform” rating in a research report on Tuesday. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. BMO Capital Markets reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Tuesday, January 13th. Finally, Argus lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $133.52.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: NEJM published full Phase 3 ASCENT-04/KEYNOTE-D19 results showing Trodelvy® (sacituzumab govitecan) + Keytruda® met the primary endpoint with a 35% PFS improvement (HR 0.65), supporting the combination as a potential new first-line standard in PD-L1+ metastatic TNBC — a meaningful commercial upside for Gilead’s Trodelvy franchise. New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results
• Positive Sentiment: Rothschild & Co Redburn raised its GILD price target to $159 and kept a “buy” rating, signaling institutional confidence and providing upside thesis support to momentum traders and fundamental buyers. Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences
• Positive Sentiment: Investor commentary highlights margin expansion and stronger free cash flow as underappreciated drivers for Gilead’s valuation, supporting buy-side interest beyond the clinical story. Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
• Neutral Sentiment: Market commentary includes a valuation check after recent share-price softness — useful context for investors assessing whether the recent run is a buy-the-news move or a reset toward fair value. Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness
• Neutral Sentiment: Technical/relative-strength pieces note improved momentum in GILD, which can attract momentum traders but doesn’t change fundamentals by itself. Stocks generating improved relative strength: Gilead Sciences
• Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at $123.50) and reduced his stake by ~35.9% — an insider sale that may prompt investor questions about timing or tax/liquidity motives. SEC Filing — Form 4
• Negative Sentiment: RBC raised its target slightly to $103 but kept a “sector perform” rating — that target sits well below current levels and represents a cautious analyst view that could cap upside if other brokers follow suit. RBC Lifts Price Target on Gilead Sciences to $103

Gilead Sciences Stock Performance

Shares of GILD opened at $129.11 on Thursday. The company has a market capitalization of $160.18 billion, a price-to-earnings ratio of 20.02, a price-to-earnings-growth ratio of 0.65 and a beta of 0.33. Gilead Sciences, Inc. has a 52-week low of $91.84 and a 52-week high of $129.39. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock has a 50 day moving average price of $123.64 and a 200 day moving average price of $118.37.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.4%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer owned 153,503 shares of the company’s stock, valued at approximately $18,727,366. This trade represents a 1.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares of the company’s stock, valued at $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 141,757 shares of company stock valued at $17,569,112 over the last ninety days. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.